Pfizer

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE182A01018
NSEID: PFIZER
BSEID: 500680

INR

4,999.00

-3.8 (-0.08%)

BSENSE

Dec 05

BSE+NSE Vol: 2.21 k

{
  "main_header": {
    "sid": 970356,
    "name": "Pfizer",
    "stock_name": "Pfizer",
    "full_name": "Pfizer Ltd.",
    "name_url": "stocks-analysis/pfizer",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "4,999.00",
    "chg": -3.8,
    "chgp": "-0.08%",
    "dir": -1,
    "prev_price": "5,002.80",
    "mcapval": "22,842.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 500680,
    "symbol": "PFIZER",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE182A01018",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "2.21 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pfizer-970356-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Pfizer's Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pfizer-downgraded-to-sell-amid-technical-weakness-and-valuation-concerns-3740717",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Pfizer_mojoScore_3740717.png",
        "date": "2025-12-02 08:46:16",
        "description": "Pfizer's recent market evaluation reveals a nuanced picture shaped by contrasting financial trends, valuation metrics, and technical indicators. While the pharmaceutical giant demonstrates solid profitability and management efficiency, its stock performance and technical outlook suggest caution for investors navigating the current landscape."
      },
      {
        "title": "Pfizer Shares Reflect Shift in Technical Momentum Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/pfizer-shares-edge-lower-amid-mixed-technical-signals-and-weak-momentum-3740274",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Pfizer_technicaldot_3740274.png",
        "date": "2025-12-02 08:10:11",
        "description": "Pfizer's stock price has exhibited a subtle shift in momentum, with recent technical indicators signalling a transition from mildly bullish to mildly bearish trends. This development comes amid a backdrop of mixed signals from key momentum and trend-following tools, highlighting a nuanced market assessment for the pharmaceutical giant."
      },
      {
        "title": "How has been the historical performance of Pfizer?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-pfizer-3739315",
        "imagepath": "",
        "date": "2025-12-01 23:23:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Income Trends</strong></p>\n<p>Pfizer demonstrated consistent growth in net sales, rising from ₹676.69 crores in 2007 to ₹772.27 crores by November 2009. This upward trend was complemented by a gradual increase in other operating income, which reached ₹24.37 crores in 2009, up from negligible amounts in earlier years. Consequently, total operating income expanded from ₹676.69 crores in 2007 to ₹796.64 crores in 2009, reflecting the company's ability to enhance its top-line performance despite a challenging pharmaceutical market environment.</p>\n<p>Raw material costs and manufacturing expenses also increased in line with revenue growth, with raw material costs rising from ₹139.71 crores in 2007 to ₹198.67 crores in 2009, and manufacturing expenses climbing from ₹205.71 cr..."
      },
      {
        "title": "Pfizer’s Evaluation Revised Amidst Mixed Financial and Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pfizer-downgraded-from-buy-to-hold-by-marketsmojo-amid-valuation-concerns-3730753",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Pfizer_mojoScore_3730753.png",
        "date": "2025-11-26 09:46:59",
        "description": "Pfizer’s recent assessment has been revised, reflecting a nuanced view of its current market position and financial health. The changes in evaluation metrics stem from a combination of valuation concerns, steady financial trends, and technical indicators, set against a backdrop of subdued stock returns and sector dynamics."
      },
      {
        "title": "How has been the historical performance of Pfizer?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-pfizer-3695466",
        "imagepath": "",
        "date": "2025-11-13 00:25:58",
        "description": "Answer:\nPfizer's historical performance shows a trend of fluctuating net sales and profits over the years. \n\nBreakdown:\nIn November 2009, Pfizer reported net sales of 772.27 Cr, an increase from 681.70 Cr in November 2008, and 676.69 Cr in both December and November 2007. Total operating income also rose to 796.64 Cr in November 2009 from 704.60 Cr in November 2008. However, the total expenditure increased to 638.47 Cr in November 2009 from 552.36 Cr in November 2008. Operating profit, excluding other income, was 158.17 Cr in November 2009, slightly up from 152.24 Cr in November 2008, while the overall operating profit, including other income, was 229.22 Cr in November 2009 compared to 222.35 Cr in November 2008. Profit before tax decreased significantly to 210.01 Cr in November 2009 from 419.13 Cr in November 2008, leading to a profit after tax of 137.12 Cr in November 2009, down from 299.58 Cr in November..."
      },
      {
        "title": "When is the next results date for Pfizer?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-pfizer-3672482",
        "imagepath": "",
        "date": "2025-11-04 23:21:21",
        "description": "The next results date for Pfizer is scheduled for November 12, 2025...."
      },
      {
        "title": "Why is Pfizer falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pfizer-fallingrising-3662893",
        "imagepath": "",
        "date": "2025-10-31 22:58:40",
        "description": "As of 31-Oct, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,215.00, which reflects a decrease of 86.75 or 1.64%. The stock has underperformed its sector by 1.19% today, and while it is higher than the 200-day moving average, it is lower than the 5-day, 20-day, 50-day, and 100-day moving averages. Over the past week, the stock has decreased by 2.26%, contrasting with a 1.25% increase over the past month. Despite a high dividend yield of 3.12% and rising investor participation, as indicated by a 56.08% increase in delivery volume, the overall performance remains weak. The company boasts high management efficiency with a return on equity of 18.22% and a low debt-to-equity ratio, which are positive indicators; however, these factors have not been sufficient to support the stock price in the current market environment.\n\nIn the broader market context, Pfizer's recent performance has bee..."
      },
      {
        "title": "Why is Pfizer falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pfizer-fallingrising-3616016",
        "imagepath": "",
        "date": "2025-10-13 22:39:35",
        "description": "As of 13-Oct, Pfizer Ltd. is experiencing a price increase, currently at 5,509.00, reflecting a rise of 180.85 or 3.39%. The stock has outperformed its sector today by 3.54% and has shown a consecutive gain over the last three days, accumulating a total return of 6.24% during this period. Additionally, Pfizer is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Despite a decline in delivery volume by 43.49% against the 5-day average, the company boasts a high dividend yield of 3.1% and strong management efficiency, evidenced by a high return on equity (ROE) of 18.22% and a low debt-to-equity ratio.\n\nIn the broader market context, Pfizer's short-term performance over the past week shows a return of 5.52%, significantly outperforming the Sensex, which only increased by 0.66%. However, over the year, Pfizer's performance has lagged behind the bench..."
      },
      {
        "title": "Why is Pfizer falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-pfizer-fallingrising-3608436",
        "imagepath": "",
        "date": "2025-10-09 22:59:06",
        "description": "As of 09-Oct, Pfizer Ltd. has experienced a price increase, currently trading at 5,260.00, reflecting a rise of 74.35 or 1.43%. The stock opened with a gain of 2.95% today and reached an intraday high of Rs 5,338.5. Despite this positive movement, there has been a notable decline in investor participation, with delivery volume dropping by 70.88% compared to the 5-day average. The stock has outperformed its sector by 0.49% today, and while it has shown a modest increase of 2.12% over the past week, it remains down 7.98% over the past year. Positive factors contributing to the stock's performance include high management efficiency, indicated by a return on equity (ROE) of 18.22%, and a low debt-to-equity ratio, which supports its stability.\n\nIn the broader market context, Pfizer's short-term performance has outpaced the Sensex, which has risen by 1.47% over the same week. However, the year-to-date performance..."
      }
    ],
    "total": 325,
    "sid": "970356",
    "stock_news_url": "https://www.marketsmojo.com/news/pfizer-970356"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
      "datetime": "12-Nov-2025",
      "details": "Pursuant to Regulations 30 and 33 of the Listing Regulations we submit herewith the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2025 which were inter alia approved by the Board of Directors of the Company at their Meeting held today i.e. November 12 2025 that commenced at 2.00 p.m. and concluded at 3.15 p.m.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.",
      "datetime": "03-Nov-2025",
      "details": "Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday November 12 2025 inter alia to consider approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2025.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Oct-2025",
      "details": "Certificate under SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Pfizer Ltd. has declared <strong>350%</strong> dividend, ex-date: 09 Jul 25",
          "dt": "2025-07-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Pfizer's Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts

2025-12-02 08:46:16

Pfizer's recent market evaluation reveals a nuanced picture shaped by contrasting financial trends, valuation metrics, and technical indicators. While the pharmaceutical giant demonstrates solid profitability and management efficiency, its stock performance and technical outlook suggest caution for investors navigating the current landscape.

Pfizer Shares Reflect Shift in Technical Momentum Amid Mixed Market Signals

2025-12-02 08:10:11

Pfizer's stock price has exhibited a subtle shift in momentum, with recent technical indicators signalling a transition from mildly bullish to mildly bearish trends. This development comes amid a backdrop of mixed signals from key momentum and trend-following tools, highlighting a nuanced market assessment for the pharmaceutical giant.

How has been the historical performance of Pfizer?

2025-12-01 23:23:37

Revenue and Operating Income Trends

Pfizer demonstrated consistent growth in net sales, rising from ₹676.69 crores in 2007 to ₹772.27 crores by November 2009. This upward trend was complemented by a gradual increase in other operating income, which reached ₹24.37 crores in 2009, up from negligible amounts in earlier years. Consequently, total operating income expanded from ₹676.69 crores in 2007 to ₹796.64 crores in 2009, reflecting the company's ability to enhance its top-line performance despite a challenging pharmaceutical market environment.

Raw material costs and manufacturing expenses also increased in line with revenue growth, with raw material costs rising from ₹139.71 crores in 2007 to ₹198.67 crores in 2009, and manufacturing expenses climbing from ₹205.71 cr...

Pfizer’s Evaluation Revised Amidst Mixed Financial and Market Signals

2025-11-26 09:46:59

Pfizer’s recent assessment has been revised, reflecting a nuanced view of its current market position and financial health. The changes in evaluation metrics stem from a combination of valuation concerns, steady financial trends, and technical indicators, set against a backdrop of subdued stock returns and sector dynamics.

How has been the historical performance of Pfizer?

2025-11-13 00:25:58

Answer: Pfizer's historical performance shows a trend of fluctuating net sales and profits over the years. Breakdown: In November 2009, Pfizer reported net sales of 772.27 Cr, an increase from 681.70 Cr in November 2008, and 676.69 Cr in both December and November 2007. Total operating income also rose to 796.64 Cr in November 2009 from 704.60 Cr in November 2008. However, the total expenditure increased to 638.47 Cr in November 2009 from 552.36 Cr in November 2008. Operating profit, excluding other income, was 158.17 Cr in November 2009, slightly up from 152.24 Cr in November 2008, while the overall operating profit, including other income, was 229.22 Cr in November 2009 compared to 222.35 Cr in November 2008. Profit before tax decreased significantly to 210.01 Cr in November 2009 from 419.13 Cr in November 2008, leading to a profit after tax of 137.12 Cr in November 2009, down from 299.58 Cr in November...

When is the next results date for Pfizer?

2025-11-04 23:21:21

The next results date for Pfizer is scheduled for November 12, 2025....

Why is Pfizer falling/rising?

2025-10-31 22:58:40

As of 31-Oct, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,215.00, which reflects a decrease of 86.75 or 1.64%. The stock has underperformed its sector by 1.19% today, and while it is higher than the 200-day moving average, it is lower than the 5-day, 20-day, 50-day, and 100-day moving averages. Over the past week, the stock has decreased by 2.26%, contrasting with a 1.25% increase over the past month. Despite a high dividend yield of 3.12% and rising investor participation, as indicated by a 56.08% increase in delivery volume, the overall performance remains weak. The company boasts high management efficiency with a return on equity of 18.22% and a low debt-to-equity ratio, which are positive indicators; however, these factors have not been sufficient to support the stock price in the current market environment. In the broader market context, Pfizer's recent performance has bee...

Why is Pfizer falling/rising?

2025-10-13 22:39:35

As of 13-Oct, Pfizer Ltd. is experiencing a price increase, currently at 5,509.00, reflecting a rise of 180.85 or 3.39%. The stock has outperformed its sector today by 3.54% and has shown a consecutive gain over the last three days, accumulating a total return of 6.24% during this period. Additionally, Pfizer is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Despite a decline in delivery volume by 43.49% against the 5-day average, the company boasts a high dividend yield of 3.1% and strong management efficiency, evidenced by a high return on equity (ROE) of 18.22% and a low debt-to-equity ratio. In the broader market context, Pfizer's short-term performance over the past week shows a return of 5.52%, significantly outperforming the Sensex, which only increased by 0.66%. However, over the year, Pfizer's performance has lagged behind the bench...

Why is Pfizer falling/rising?

2025-10-09 22:59:06

As of 09-Oct, Pfizer Ltd. has experienced a price increase, currently trading at 5,260.00, reflecting a rise of 74.35 or 1.43%. The stock opened with a gain of 2.95% today and reached an intraday high of Rs 5,338.5. Despite this positive movement, there has been a notable decline in investor participation, with delivery volume dropping by 70.88% compared to the 5-day average. The stock has outperformed its sector by 0.49% today, and while it has shown a modest increase of 2.12% over the past week, it remains down 7.98% over the past year. Positive factors contributing to the stock's performance include high management efficiency, indicated by a return on equity (ROE) of 18.22%, and a low debt-to-equity ratio, which supports its stability. In the broader market context, Pfizer's short-term performance has outpaced the Sensex, which has risen by 1.47% over the same week. However, the year-to-date performance...

View All News

Announcement

Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025

12-Nov-2025 | Source : BSE

Pursuant to Regulations 30 and 33 of the Listing Regulations we submit herewith the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2025 which were inter alia approved by the Board of Directors of the Company at their Meeting held today i.e. November 12 2025 that commenced at 2.00 p.m. and concluded at 3.15 p.m.

Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.

03-Nov-2025 | Source : BSE

Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday November 12 2025 inter alia to consider approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2025.